Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer
Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer
复制标题
DOI：
10.1172/jci3145
复制
发表时间：
1998-08-01
影响因子：
15.9
通讯作者：
Strieter, RM
中科院分区：
文献类型：
--
作者：
Arenberg, DA;Keane, MP;Strieter, RM
我们在此报告了 CXC 趋化因子、上皮中性粒细胞激活肽 (ENA-78) 作为血管生成因子在人类非小细胞肺癌 (NSCLC) 中的作用。在新鲜分离的 NSCLC 人类样本中，发现 ENA-78 水平升高，与肿瘤的血管分布密切相关。在人类 NSCLC 肿瘤发生的 SCID 小鼠模型中，ENA-78 在肿瘤中的表达与两种不同 NSCLC 细胞系中的肿瘤生长相关。此外，用中和性抗ENA-78抗体对携带NSCLC肿瘤的小鼠进行被动免疫可减少肿瘤生长、肿瘤血管分布和自发转移，同时在体外或体内对NSCLC细胞的增殖没有影响。这些发现表明 ENA-78 是人类 NSCLC 中重要的血管生成因子。
We report here the role of the CXC chemokine, epithelial neutrophil activating peptide (ENA-78), as an angiogenic factor in human non-small cell lung cancer (NSCLC), In freshly isolated human specimens of NSCLC, elevated levels of ENA-78 were found that strongly correlated with the vascularity of the tumors. In a SCID mouse model of human NSCLC tumorigenesis, expression of ENA-78 in developing tumors correlated with tumor growth in two different NSCLC cell lines. Furthermore, passive immunization of NSCLC tumor-bearing mice with neutralizing anti-ENA-78 antibodies reduced tumor growth, tumor vascularity, and spontaneous metastases, while having no effect on the proliferation of NSCLC cells either in vitro or in vivo. These findings suggest that ENA-78 is an important angiogenic factor in human NSCLC.